Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -3.41%75 ROC (Joel Greenblatt) % is 17.81% as of Mar. 2026, which is 2% below its 10-year median of 18.13. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 982 Drug Manufacturers companies, Phibro Animal Health ranks better than 62.12% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Phibro Animal Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 17.81%.
The historical rank and industry rank for Phibro Animal Health's ROC (Joel Greenblatt) % or its related term are showing as below:
PAHC'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.73 Med: 18.13 Max: 30.64
Current: 18.97
During the past 13 years, Phibro Animal Health's highest ROC (Joel Greenblatt) % was 30.64%. The lowest was 5.73%. And the median was 18.13%.
PAHC's ROC (Joel Greenblatt) % is ranked better than 62.12% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.28
vs PAHC: 18.97
Phibro Animal Health's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -13.10% per year.
Phibro Animal Health (NAS:PAHC) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Phibro Animal Health ROC (Joel Greenblatt) % Related Terms
Phibro Animal Health ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phibro Animal Health ROC (Joel Greenblatt) % Chart
PAHC vs PRGO, HROW, XERS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's ROC (Joel Greenblatt) % falls into.
Phibro Animal Health ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 17.81% mean?
Phibro Animal Health (PAHC) has a ROC (Joel Greenblatt) % of 17.81% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Phibro Animal Health and its competitors. This is near median its historical median of 18.13. Over the past decade, Phibro Animal Health's ROC (Joel Greenblatt) % has ranged from 5.73 to 30.64. According to the industry distribution chart, Phibro Animal Health ranks #372 out of 982 companies in the Drug Manufacturers industry, placing it in the top 37.9%.
Is Phibro Animal Health's ROC (Joel Greenblatt) % too high?
Phibro Animal Health's current ROC (Joel Greenblatt) % of 17.81% is near median its 10-year median of 18.13. Over the past 10 years, this metric has ranged from a low of 5.73 to a high of 30.64. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.28. Phibro Animal Health's value of 17.81% is 57.9% above this industry median. Based on the distribution chart, Phibro Animal Health ranks #372 out of 982 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's ROC (Joel Greenblatt) % compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #372 out of 982 companies for ROC (Joel Greenblatt) %. This puts Phibro Animal Health in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.28. Phibro Animal Health's value of 17.81% is 57.9% above this benchmark. Historically, Phibro Animal Health's own ROC (Joel Greenblatt) % has ranged from 5.73 to 30.64 over the past decade. While the company's 10-year median is 18.13 vs. the industry median of 11.28, Phibro Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.28, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current ROC (Joel Greenblatt) % of 17.81% is 57.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current ROC (Joel Greenblatt) % is 17.81%, which is near median its own 10-year median of 18.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current ROC (Joel Greenblatt) % is 17.81%, which is near median its 10-year median of 18.13 and 57.9% above the Drug Manufacturers industry median of 11.28. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current ROC (Joel Greenblatt) % is 17.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
ROC (Joel Greenblatt) %: 17.81% (near median its 10-year median of 18.13)
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 57.9% above the Drug Manufacturers median (#372 of 982)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
